New JAVMA data support earlier renal diets in cats with CKD: full analysis

A newly published JAVMA paper is giving clinicians a concrete number for the benefit of early renal nutrition in cats with CKD: about five extra months of survival over a three-year window. The retrospective study, authored largely by IDEXX-affiliated investigators, reviewed records from 1,430 cats with early-stage CKD in the US and Canada and found that continuous treatment with a veterinary therapeutic renal diet was associated with slower progression and improved survival. (pubmed.ncbi.nlm.nih.gov)

The finding lands in a part of feline medicine where practice has often outpaced hard data. Therapeutic kidney diets have long been a cornerstone of CKD management in more advanced disease, supported by earlier studies showing fewer uremic crises, fewer renal-related deaths, and longer survival in cats that accepted those diets. But the evidence base for stage 1 disease has been thinner, and current IRIS materials still frame kidney diets most directly around stages 2, 3, and 4, while stage 1 management depends more on the broader clinical context, including phosphorus control and related biomarkers. (todaysveterinarypractice.com)

In the new study, cats born between January 1, 2010, and December 31, 2014, and diagnosed with early-stage CKD were randomly selected from a commercial veterinary medical records database. Of the 1,430 cats included, 839 received a veterinary therapeutic renal diet and 591 did not. The authors reported a 45% lower hazard of progression for treated stage 1 cats, a 46% lower hazard for treated stage 2 cats with creatinine within the reference interval, and a 41% lower hazard for treated stage 2 cats with creatinine above the reference interval. Survival over three years was also longer in treated cats, with restricted mean survival time of 31.0 months versus 26.0 months in untreated cats. (pubmed.ncbi.nlm.nih.gov)

IDEXX's companion summary adds more practice-facing detail. It states that treated cats had roughly a one-year delay in progression to a later IRIS stage, a 30% lower risk of all-cause mortality in the first three years after diagnosis, and longer average survival among cats that died during that period. The same summary argues that many early-stage cats are asymptomatic and makes the case that routine wellness blood work, including renal biomarkers, is what creates the window for intervention before appetite and clinical status decline. (ca.idexx.com)

Outside commentary has focused less on whether renal nutrition matters and more on when to start, and how to get cats to accept it. Coverage discussing the paper has highlighted a familiar challenge in practice: pet parent resistance to changing food for a cat that seems normal at home. Other CKD guidance pieces have made a similar point for years, noting that earlier introduction may improve acceptance before nausea, weight loss, or food aversion complicate the transition. (thevetiverse.com)

Why it matters: For general practitioners and feline-focused teams, this study gives a stronger evidence base for a recommendation that can otherwise feel abstract. A five-month survival gain and slower progression are easier to discuss with pet parents than a general message about “supporting kidney health.” It also sharpens the operational side of CKD care: catching disease earlier through routine screening, documenting stage carefully, revisiting diet recommendations more than once, and monitoring whether the cat is actually eating enough of the prescribed food. That last point matters because nutritional success in CKD is never just about the label on the bag or can; caloric intake, body weight, muscle condition, hydration, phosphorus control, and individual tolerance still determine whether the plan works in the real world. (pubmed.ncbi.nlm.nih.gov)

The study also raises a strategic question for the profession. If early renal diets are associated with better outcomes, why aren't more cats getting them consistently? IDEXX's materials suggest uptake remains limited, and that gap likely reflects a mix of guideline ambiguity in stage 1 disease, palatability issues, cost concerns, and the difficulty of persuading pet parents to make a therapeutic switch before a cat looks sick. That makes this less a nutrition story alone than a communication and workflow story for practices. (ca.idexx.com)

What to watch: The next step is whether this real-world evidence shifts guideline interpretation, conference messaging, and day-to-day prescribing behavior for IRIS stage 1 and early stage 2 cats, or whether clinicians continue to reserve stronger diet pushes for cats with clearer biochemical progression, phosphorus concerns, or rising FGF-23. (iris-kidney.com)